XORTX Broadcasts Submitting and Mailing of the Assembly Paperwork in Reference to the Annual and Particular Assembly of Shareholders

Article content material

CALGARY, Alberta, Aug. 23, 2024 (GLOBE NEWSWIRE) — XORTX Therapeutics Inc. (“XORTX” or the “Firm”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage scientific pharmaceutical firm centered on growing revolutionary therapies to deal with progressive kidney illness, is happy to announce the administration data round (the “Round”) for the annual and particular assembly (the “Assembly”) of shareholders is now out there on the Firm’s web site at https://www.xortx.com/buyers/news-events/ir-calendar/element/7671/annual-and-special-meeting-of-shareholders in addition to on the Firm’s SEDAR+ profile (www.sedarplus.ca) and the SEC’s web site (www.sec.gov). The mailing of the Round and associated Assembly supplies occurred on August 21, 2024.

Article content material

XORTX will maintain the Assembly on September 12, 2024, at 10:00 am (Calgary Time) on the workplaces of the Firm at 3710 – thirty third Road NW, Calgary.

     Your vote is vital regardless of what number of shares you maintain. Vote at the moment.

Shareholders who’ve questions or want help with voting their shares ought to contact
     XORTX’s strategic advisor and proxy solicitation agent Laurel Hill Advisory Group by phone at
1-877-452-7184 or by e mail at help@laurelhill.com.

The Board of Administrators of XORTX recommends that Shareholders
vote FOR ALL proposed gadgets

Shareholders are inspired to learn the Round and vote your shares as quickly as potential. The deadline for voting your shares is at 10:00 am (Calgary Time) on Tuesday, September 10, 2024.

Throughout the Round, XORTX gives clarification of a misreported assertion – disclosure of Patrick Treanor’s board attendance within the Round underneath the part Participation of Administrators in Board Conferences was incorrectly reported. Patrick Treanor was not a member of the board on the time any of the seven conferences for the 12 months 2023 happened. Subsequently, his “Attendance / Variety of Board Conferences” report would extra precisely be disclosed as 0/0 versus 0/7.

Article content material

Article content material

About XORTX Therapeutics Inc.

XORTX is a pharmaceutical firm with two clinically superior merchandise in growth: 1) our lead, XRx-008 program for ADPKD; and a couple of) our secondary program in XRx-101 for acute kidney and different acute organ harm related to Coronavirus / COVID-19 an infection. As well as, XRx-225 is a pre-clinical stage program for Sort 2 Diabetic Nephropathy. XORTX is working to advance its scientific growth stage merchandise that focus on aberrant purine metabolism and xanthine oxidase to lower or inhibit manufacturing of uric acid. At XORTX, we’re devoted to growing drugs to enhance the standard of life and future well being of sufferers. Further data on XORTX is offered at www.xortx.com.

For extra data, please contact:

Neither the TSX Enterprise Change nor Nasdaq has accredited or disapproved the contents of this information launch. No inventory change, securities fee or different regulatory authority has accredited or disapproved the data contained herein.

Article content material

Ahead Trying Statements

This press launch comprises specific or implied forward-looking statements pursuant to relevant securities legal guidelines. These forward-looking statements embody, however should not restricted to, the Firm’s beliefs, plans, targets, goals, expectations, assumptions, estimates, intentions, future efficiency, different statements that aren’t historic information and statements recognized by phrases equivalent to “expects”, “anticipates”, “intends”, “plans”, “believes”, “seeks”, “estimates” or phrases of comparable which means. These forward-looking statements and their implications are based mostly on the present expectations of the administration of XORTX solely, and are topic to a variety of elements and uncertainties that might trigger precise outcomes to vary materially from these described within the forward-looking statements. Such dangers, uncertainties, and different elements embody, however should not restricted to, our capacity to acquire extra financing; the accuracy of our estimates relating to bills, future revenues and capital necessities; the success and timing of our preclinical research and scientific trials; the efficiency of third-party producers and contract analysis organizations; our plans to develop and commercialize our product candidates; our plans to advance analysis in different kidney illness functions; and, our capacity to acquire and keep mental property safety for our product candidates. Besides as in any other case required by relevant legislation and inventory change guidelines, XORTX undertakes no obligation to publicly launch any revisions to those forward-looking statements to replicate occasions or circumstances after the date hereof or to replicate the prevalence of unanticipated occasions. Extra detailed details about the dangers and uncertainties affecting XORTX is contained underneath the heading “Danger Components” in XORTX’s Annual Report on Type 20-F filed with the SEC, which is offered on the SEC’s web site, www.sec.gov (together with any paperwork forming an element thereof or integrated by reference therein), in addition to in our studies, public disclosure paperwork and different filings with the securities commissions and different regulatory our bodies in Canada, which can be found on www.sedarplus.ca.

Article content material